|
Cutaneous form of the disease: limited / diffuse
|
23 (57) / 17 (43)
|
|
Digital pitting scars
|
6 (15)
|
|
Pulmonary arterial pressure (PAP)
| |
|
mmHg [mean ± SD (range)]
|
33 ± 6 (21–48)
|
|
>40 mmHg
|
6 (15)
|
|
Pulmonary fibrosis (computed tomography scan)
|
16 (40)
|
|
Forced vital capacity below 75% of normal values
|
9 (23)
|
|
Decreased carbon monoxide diffusing capacity (DLCO/Hb <75%)
|
16 (40)
|
|
Left ventricular ejection fraction (%) (mean ± SD%)
|
62 ± 8
|
|
Antinuclear antibodies ≥1/160
|
38 (92)
|
|
Anti-topoisomerase I antibodies/anti-centromere antibodies
|
12/7
|
|
Creatininaemia (μmol) (mean ± SD)
|
79 ± 13
|
|
Erythrocyte sedimentation rate (mm/1st hour) (mean ± SD)
|
21 ± 18
|
|
C-reactive protein (mg/l) (mean ± SD)
|
11 ± 16
|
|
Ongoing low-dose prednisone (no. patients) (mean mg/day ± SD)
|
14 (7.4 ± 2)
|
|
Ongoing angiotensin-converting enzyme inhibitors (no. patients)
|
7
|
|
Ongoing low-dose aspirin therapy (no. patients)
|
25
|
